What is the next big thing for your company's portfolio?
To help pharmaceutical companies answer this question, Kaiser Associates conducted a comprehensive analysis of nearly every pharma R&D program in the world and compiled the findings into the second annual Hot Indications List.The 2016 edition includes:
- An updated Top 200 List of indications
- Analysis of some of the biggest 'movers and losers' from last year's list
- Insights on recent acquisitions, drug approvals, and pipeline activity
Complete the form to download your free whitepaper now!